NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Index- P/E- EPS (ttm)-0.35 Insider Own4.78% Shs Outstand82.61M Perf Week6.82%
Market Cap116.54M Forward P/E- EPS next Y-0.48 Insider Trans0.00% Shs Float78.70M Perf Month0.00%
Enterprise Value100.46M PEG- EPS next Q-0.10 Inst Own9.46% Short Float2.43% Perf Quarter65.88%
Income-25.77M P/S- EPS this Y2.04% Inst Trans3.05% Short Ratio9.91 Perf Half Y-2.08%
Sales0.00M P/B9.53 EPS next Y-32.54% ROA-126.69% Short Interest1.91M Perf YTD10.16%
Book/sh0.15 P/C7.20 EPS next 5Y11.59% ROE-190.61% 52W High2.63 -46.39% Perf Year-28.79%
Cash/sh0.20 P/FCF- EPS past 3/5Y13.79% 1.30% ROIC-209.52% 52W Low0.77 82.90% Perf 3Y5.22%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility8.53% 7.05% Perf 5Y-18.50%
Dividend TTM- EV/Sales- EPS Y/Y TTM-0.82% Oper. Margin- ATR (14)0.10 Perf 10Y-
Dividend Ex-Date- Quick Ratio3.26 Sales Y/Y TTM- Profit Margin- RSI (14)53.54 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio3.26 EPS Q/Q30.93% SMA200.97% Beta1.04 Target Price8.87
Payout- Debt/Eq0.01 Sales Q/Q- SMA5011.25% Rel Volume0.22 Prev Close1.40
Employees22 LT Debt/Eq0.01 EarningsMay 16 BMO SMA2000.86% Avg Volume192.60K Price1.41
IPOJan 15, 2019 Option/ShortYes / Yes EPS/Sales Surpr.13.33% - Trades Volume2,106 Change0.71%
Date Action Analyst Rating Change Price Target Change
Jun-02-25Initiated H.C. Wainwright Buy $9
Jan-28-25Initiated Rodman & Renshaw Buy $7
Jun-26-24Initiated ROTH MKM Buy $10
Apr-22-24Initiated H.C. Wainwright Buy $9
May-29-25 07:27AM
May-27-25 07:27AM
Apr-29-25 07:27AM
Apr-22-25 07:21AM
Apr-16-25 07:27AM
07:27AM Loading…
Apr-01-25 07:27AM
Mar-03-25 07:27AM
Feb-20-25 07:27AM
Feb-04-25 07:27AM
Dec-19-24 08:30AM
08:30AM
Nov-18-24 11:37AM
Nov-13-24 08:00AM
Oct-22-24 02:30AM
Oct-11-24 08:39AM
09:09AM Loading…
Oct-10-24 09:09AM
Oct-09-24 07:58AM
Oct-08-24 04:01PM
Sep-24-24 07:27AM
Sep-10-24 07:27AM
Aug-12-24 10:53PM
Jun-27-24 12:29PM
Jun-25-24 07:27AM
Jun-17-24 07:00AM
Jun-13-24 07:58AM
Jun-11-24 06:00AM
Jun-03-24 07:00AM
May-28-24 07:00AM
May-14-24 10:53PM
07:27AM
12:19PM Loading…
May-13-24 12:19PM
Apr-02-24 09:53AM
06:00AM
Mar-04-24 08:28PM
Feb-21-24 07:27AM
Feb-15-24 07:27AM
Jan-24-24 07:27AM
Jan-09-24 07:27AM
Dec-05-23 07:27AM
Nov-16-23 05:30AM
Nov-01-23 07:27AM
Oct-20-23 05:00PM
Oct-13-23 09:24AM
Oct-11-23 01:05PM
Oct-10-23 06:00AM
Sep-27-23 09:34AM
Sep-26-23 07:27AM
Sep-19-23 07:27AM
Aug-09-23 07:27AM
Aug-08-23 07:27AM
Jun-29-23 10:19AM
Jun-27-23 07:27AM
May-09-23 07:15AM
Mar-29-23 07:27AM
Mar-07-23 07:27AM
Jan-17-23 02:59PM
07:27AM
Dec-12-22 07:27AM
Nov-14-22 05:00PM
Nov-07-22 07:27AM
Oct-25-22 06:30AM
Oct-03-22 07:27AM
Sep-28-22 08:20AM
Sep-27-22 09:05AM
Aug-03-22 07:29AM
Jul-12-22 06:14AM
Jun-29-22 10:07AM
Jun-27-22 10:07AM
Jun-09-22 04:05PM
May-27-22 01:00PM
May-24-22 07:00AM
May-19-22 07:27AM
May-17-22 07:27AM
May-02-22 02:42PM
Mar-24-22 07:27AM
Mar-22-22 07:27AM
Mar-15-22 07:27AM
Mar-01-22 07:27AM
Feb-02-22 06:30AM
Jan-19-22 07:27AM
Nov-05-21 09:18AM
Nov-04-21 08:52AM
Nov-03-21 08:36AM
Nov-02-21 04:04PM
Oct-25-21 07:27AM
Oct-18-21 07:27AM
Sep-16-21 07:27AM
Sep-10-21 04:33PM
Sep-07-21 07:27AM
Aug-24-21 07:27AM
Aug-19-21 06:52AM
Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.